Adequate suppression of platelet reactivity is necessary to mitigate early thrombotic events, including stent thrombosis, among patient undergoing percutaneous coronary intervention (PCI). Clinical trials conducted…
Abstract Background There are no studies specifically designed to rule out a drug-drug interaction (DDI) when cangrelor is used among patients who have been pretreated with ticagrelor. Objectives…
Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing Francesco Franchi, MD, Fabiana Rollini, MD, Jose Rivas, MD, Andrea Rivas,…
Footnotes Data sharing: The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or…
Overview Cangrelor is an intravenous P2Y12 inhibitor utilized as a bridge to achieve adequate platelet inhibition until oral P2Y12 inhibitors achieve their full antiplatelet effects…
ABSTRACT Introduction Patients with cardiovascular disease are commonly affected by a number of comorbidities leading to a high prevalence of polypharmacy. Polypharmacy increases the probability…
Abstract Purpose. Genotype-guided antiplatelet therapy is increasingly being incorporated into clinical care. The purpose of this study is to determine the extent to which patients…
A review of the anticoagulant and antiplatelet agents currently available for the treatment of STEMI patients undergoing PPCI. Acute ST-segment elevation myocardial infarction (STEMI) comprises…